EXPERIENCE WITH THE NEW THROMBOLYTIC DRUG RECOMBINANT TISSUE-PLASMINOGEN ACTIVATOR IN PATIENTS WITH MYOCARDIAL-INFARCTION

Search for more effective and safe drugs has recently led to the desig n of second-generation thrombolytic enzymes one of which is recombinan t tissue plasminogen activator. A total of 80 patients including 41 wh o received tissue plasminogen activator (TPA) (Group 1), 39 on strepto kinase (SK) (Group 2) were examined. By the 90th minute of thrombolyti c infusion, coronary blood flow was recovered in 27 (66%) patients fro m Group 1 and 19 (49%) from Group 2 (p=0.12). A decrease in fibrinogen concentration by less than 1 g/l was seen in 7 (18.4%) patients from Group 1 and in 29 (82.9%) patients from Group 2 (p=0.00005). The level s of fibrinogen and plasminogen during 36 hours of initiation of throm bolytic infusion were statistically significantly lower in Group 2. Th e incidence of hemorrhages was the same in the two groups and equal to 26.8 and 28.0% in Groups 1 and 2, respectively. All the patients had no hemorrhages requiring transfusion of blood and its substitutes, as well as no cerebral circulatory disorders in the first week of the dis ease.